CCLD
CareCloud, Inc.
CCLD has slightly lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over CCLD overall, supported by stronger fundamentals and stronger modeled upside.
CCLD Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Strong |
CCLD's revenue, profitability, cash flow and balance sheet are all currently healthy.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CCLD PE Valuation
CCLD has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
CCLD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect CCLD's earnings to grow and its profitability to improve, with its revenue holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over CCLD on the outlook, with more favorable revenue expectations.
CCLD Earnings Per Share
CCLD has returned to profit: it earned $0.13 per share over the past year, after losing money the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over CCLD in the latest year-over-year earnings comparison.
CCLD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $33.7M | +8.6% |
| Q2 2026 | $31.9M | +16% |
| Q1 2026 | $31.3M | +13% |
| Q4 2025 | $34.4M | +22% |
| Q3 2025 | $31.1M | +8.8% |
| Q2 2025 | $27.4M | -2.5% |
| Q1 2025 | $27.6M | +6.4% |
| Q4 2024 | $28.2M | -0.6% |
CCLD's revenue has grown year over year for five quarters in a row: $34M last quarter, up 8.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +9.2 points |
| Q2 2026 | 5.8% | -5.1 points |
| Q1 2026 | 3.2% | -4.1 points |
| Q4 2025 | 9.1% | -3.2 points |
| Q3 2025 | 10% | -1.1 points |
| Q2 2025 | 11% | +2.9 points |
| Q1 2025 | 7.3% | +6.8 points |
| Q4 2024 | 12% | +166 points |
CCLD has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CCLD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
CCLD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $5.3M | -18% |
| Q2 2026 | $6.5M | +4.8% |
| Q1 2026 | $3.2M | -29% |
| Q4 2025 | $6.6M | +53% |
| Q3 2025 | $6.5M | -3.5% |
| Q2 2025 | $6.2M | +50% |
| Q1 2025 | $4.5M | +19% |
| Q4 2024 | $4.3M | +28% |
CCLD generated $22M in free cash flow over the past year, about the same as the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over CCLD on cash flow, with more consistent year-over-year improvement.
CCLD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +56.4K shares |
| 1 year | +0.5% | +207K shares |
| 3 years | +181% | +27.4M shares |
| 5 years | +235% | +29.8M shares |
| Available history | +252% | +30.4M shares |
CCLD has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CCLD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.2x | Net Cash |
| Q2 2026 | -0.2x | Net Cash |
| Q1 2026 | -0.1x | Net Cash |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | 0.1x | Very low |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.3x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
CCLD has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over CCLD on leverage, with a lower net debt burden relative to earnings.
CCLD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.4 | Neutral |
| Stochastic | 48.9 | Neutral |
CCLD's weekly RSI is 58 (neutral) and its Stochastic is 49 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CCLD PE vs Healthcare Sector
| Metric | CCLD | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CCLD has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CCLD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.05 | 29% above |
| 20 week MA | $2.23 | 18% above |
| 50 week MA | $2.55 | 3.5% above |
| 100 week MA | $2.63 | 0.4% above |
| 200 week MA | $2.44 | 8.2% above |
CCLD is in an uptrend: it's above all five of its weekly moving averages, and 8.2% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
CCLD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.15 | $9.37 | +126% |
| 2021 | $9.37 | $5.53 | -41% |
| 2022 | $5.53 | $2.85 | -48% |
| 2023 | $2.85 | $1.52 | -47% |
| 2024 | $1.52 | $3.64 | +139% |
| 2025 | $3.64 | $3.04 | -16% |
| 2026 YTD | $3.04 | $2.64 | -13% |
CCLD's yearly returns have swung widely, from +139% in 2024 to −48% in 2022. It's down 13% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CCLD on returns for 2026, with the stronger performance.